Regular use of nonsteroidal anti-infl ammatory drugs (NSAIDs) is associated with a reduced risk of esophageal adenocarcinoma. Epidemiological studies examining the association between NSAID use and the risk of the precursor lesion, Barrett's esophagus, have been inconclusive.
INTRODUCTION
Th e incidence of esophageal adenocarcinoma has increased more than eightfold in the United States in recent decades ( 1 ) , and the incidence continues to rise ( 2 ) . Esophageal adenocarcinoma is a highly fatal cancer with a 5-year survival rate of <20% ( 3 ) . Th us, as with other aggressive cancers, there is strong interest in identifying chemopreventive agents that might help reduce the burden of esophageal adenocarcinoma, such as nonsteroidal anti-infl ammatory drugs (NSAIDs), statins, or acid-suppressant medications.
NSAIDs have been shown in experimental studies to have a chemopreventive eff ect on the development of esophageal adenocarcinoma, presumably by blocking cyclooxygenase (COX) isoenzymes (aspirin is an inhibitor of COX-1, whereas other NSAIDs block both COX-1 and COX-2) and the production of prostaglandin. In addition, epidemiological studies have found a strong inverse association between use of NSAIDs and the risk of esophageal adenocarcinoma. In a pooled analysis of data from the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON; http://beacon.tlvnet.net/ ), Liao et al. ( 4 ) showed that patients who used any NSAIDs had a 32% reduced risk of esophageal adenocarcinoma (summary adjusted odds ratio (OR)=0.68, 95% confi dence interval (CI)=0.56-0.83; I 2 =17%). Barrett's esophagus is the only known precursor for esophageal adenocarcinoma and may aff ect 2% of the general adult population ( 5 ) . Compared with the general population, patients with Barrett's esophagus have 10-to 55-fold increased risk of developing esophageal adenocarcinoma (6) (7) (8) (9) (10) (11) . Assessment of risk factors for Barrett's esophagus may allow for better understanding of disease pathophysiology, and identify new opportunities for prevention and risk stratifi cation. Although NSAIDs have been consistently associated with reduced risk of esophageal adenocarcinoma, it is unclear whether they may aff ect risk through preventing the development of Barrett's esophagus, by preventing the development of esophageal adenocarcinoma in patients with Barrett's esophagus, or both. Th is question has substantial clinical implications, because attempts at chemoprevention with NSAIDs in the setting of Barrett's esophagus are only logical if the eff ect of NSAIDs occurs aft er the development of Barrett's esophagus. A recent meta-analysis of fi ve studies showed a 30% reduction in the risk of progression from Barrett's esophagus to esophageal adenocarcinoma among NSAID users, as compared with nonusers ( 12 ) . In contrast, results from epidemiological studies of the association between NSAIDs and the risk of Barrett's esophagus have been largely inconclusive, where both negative (13) (14) (15) and positive associations ( 16, 17 ) have been reported.
We therefore conducted a large analysis of pooled individuallevel data from six case-control studies in the BEACON Consortium to comprehensively examine the association between use of NSAIDs and the risk of Barrett's esophagus.
METHODS

Study population
We analyzed individual-level participant data from six population-based case-control studies in BEACON that had available data on NSAID use ( Supplementary Table 1 ) . Th e six studies were as follows: the Houston Barrett's Esophagus study (based at the Michael E. DeBakey VA Medical Center at Houston, TX; hereaft er "Houston") ( 17 ) ; the Factors Infl uencing the Barrett's/Adenocarcinoma Relationship study (based in Ireland; "FINBAR") ( 13 ) ; the Epidemiology and Incidence of Barrett's Esophagus study (based in the Kaiser Permanente Northern California population; "KPNC") ( 14 ) ; Th e Newly Diagnosed Barrett's Esophagus Study (based at the University of Michigan and Ann Arbor Veterans Aff airs Medical Center at Ann Arbor, MI; "NDB") ( 18 ) ; the Study of Digestive Health (based in Brisbane, Australia; "SDH") ( 16 ) ; and the Study of Refl ux Disease (based in western Washington State; "SRD") ( 19 ) . We additionally restricted our analyses to nonHispanic white study participants due to low numbers of cases from non-white ethnic groups (total n =95; range n =17 in NDB to n =43 in KPNC). Th e institutional review boards or Research Ethics Committees of each institution approved the acquisition and pooling of data for the present analysis. Participants provided written informed consent to take part in the studies.
In all studies, cases included persons with endoscopic evidence of columnar mucosa in the tubular esophagus, accompanied by the presence of specialized intestinal metaplasia in an esophageal biopsy, and cases included persons with prevalent and newly diagnosed Barrett's esophagus ( Supplementary Table 1 ) . Th e SRD also included some patients with specialized intestinal esophageal metaplasia on biopsy, but without endoscopically visible columnar metaplasia. Th e NDB study included only males (cases and controls) ( 18 ) .
Th e cases were compared separately with ( 1 ) population-based controls, representing the underlying source population from which cases arose, and ( 2 ) gastroesophageal refl ux disease (GERD) controls, representing the population undergoing endoscopy from which cases are diagnosed.
Study variables
Data for medication use was self-reported in all studies ( Supplementary Table 1 ). Five of the six studies asked about "regular use" of medications over a specifi ed time period with a minimum frequency of use ( 13, 14, (17) (18) (19) . Th e duration of regular use varied across the fi ve studies, from 3 months to 1 year of use. Th e defi nition for frequency of regular use was consistent across the fi ve studies, each specifi ed as at least once per week. Th e remaining study did not defi ne regular use; for this study we reclassifi ed study participants as regular users if their reported frequency of use was at least once per week ( 16 ) .
Th e main exposure categories used in the analysis were regular (at least once per week) use of the medication (aspirin, non-aspirin NSAIDs, any NSAIDs) and non-regular use (referent group; less than once per week use for each category). Medication use was further classifi ed by frequency (weekly-<daily and at least daily) and duration (<5 years and ≥5 years) of use.
Potential confounding variables were available from all studies as part of a core data set and were harmonized by the coordinating center. Variables that were selected a priori as adjustment factors included age (<50, 50 to <60, 60 to <70, ≥70 years), sex (except for NDB which included only males), highest level of education (school only, tech/diploma, university), smoking status (never, former, current), and body mass index (<25, 25-29.9, ≥30 kg/m 2 ). Models that compared cases with population-based controls were also subsequently adjusted for self-reported GERD symptoms (less than weekly vs. at least weekly) to evaluate potential confounding eff ects of GERD symptoms. Frequency of GERD symptoms was defi ned as the highest reported frequency of either heartburn or acid regurgitation symptoms; "frequent symptoms" were those occurring at least weekly. 
Statistical analysis
We used multivariable logistic regression to estimate studyspecifi c ORs and 95% CIs for the association between NSAID use and risk of Barrett's esophagus. Th e study-specifi c ORs were then combined using random-eff ects meta-analytic models to generate a summary OR. We used the inconsistency index, I 2 , and its 95% uncertainty interval (UI) to assess heterogeneity between studies ( 20 ) . Larger I 2 values refl ect increasing heterogeneity, beyond what is attributable to chance. I 2 values of 25, 50, and 75% were used as evidence of low, moderate, or high levels of heterogeneity, respectively. A leave-one-out sensitivity analysis was performed by iteratively removing one study at a time to assess whether a single study was contributing to high (if present) between-study heterogeneity and to confi rm that our fi ndings were not driven by any single study ( 21 ) . For comparisons with population-based controls only, we assessed whether the association between NSAID use and the risk of Barrett's esophagus was modifi ed by frequency of GERD symptoms (less than weekly, at least weekly) by performing likelihood ratio tests of nested models with and without the NSAID-GERD interaction term.
All tests for statistical signifi cance were two-sided at α =0.05 and analyses were conducted using Stata 13.1 (StataCorp LP, College Station, TX).
RESULTS
We included data from 1,474 cases, 2,256 population-based controls, and 2,018 GERD controls in the analysis. In total, 31.7% of the study population reported regular (at least once weekly) use of aspirin, 19.6% reported regular use of non-aspirin NSAIDs, and 47.0% reported regular use of any NSAIDs. However, the prevalence of use among controls (and cases) varied considerably across the six studies ( Supplementary Table 2 ). For example, prevalence of prior regular use of aspirin in population-based controls ranged from 10.7% in SDH to 47.3% in NDB; in cases, from 17.0% in SDH to 49.6% in NDB. Figure 1a shows the association between aspirin use and risk of Barrett's esophagus. In the multivariable analysis, there was no association between prior regular use of aspirin (fully adjusted OR=1.00, 95% CI=0.76-1.32) and the risk of Barrett's esophagus for comparison with population-based controls ( Table 1 ) . We found moderate between-study heterogeneity ( I 2 =56%), but with a wide UI (95% UI=0%-82%). Among fi ve studies that reported information on frequency of use (SDH did not capture daily medication use), prior daily use of any aspirin was not associated with the risk of Barrett's esophagus (fully adjusted OR=0.93, 95% CI=0.71-1.21), with no evidence of between-study heterogeneity ( I 2 =10%). With regard to duration of use ( Table 1 ) , we found no association between duration of prior aspirin use and risk of Barrett's esophagus (fully adjusted OR for≥5 years=1.04, 95% CI=0.70-1.54; I 2 =59%). We found similar null fi ndings for aspirin use when we compared cases with GERD controls Figure 1 . Associations between NSAID use and risk of Barrett's esophagus. The summary odds ratios (OR) and 95% confi dence intervals (CIs) for the association between Barrett's esophagus and ( a ) at least weekly aspirin use; ( b ) at least weekly non-aspirin NSAID use; and ( c ) at least weekly use of any NSAIDs. Summary OR and 95% CIs were estimated using a random-effects meta-analytic model. All statistical tests were two-sided. Percentage weight describes the weighting each study contributes to the summary OR. The dot on each square represents the study-specifi c OR, and the size of the surrounding square is an illustrative representation of study weighting. The horizontal lines represents the CIs; if ending in an arrow, this indicates that the interval transcends the region plotted. ( Table 2 ) and in analyses (cases vs. population-based controls) stratifi ed by frequency of GERD symptoms ( Table 3 ) .
Aspirin
Non-aspirin NSAIDs
When compared with population-based controls, regular use of any non-aspirin NSAIDs was not associated with the risk of Barrett's esophagus (fully adjusted OR=1.16, 0.86-1.56; I 2 =49%; Figure 1b ). We found no evidence of eff ect modifi cation by frequency of GERD symptoms ( Table 3 ). Among the fi ve studies that reported information on frequency and duration of use, we found some evidence for a modest increased risk of Barrett's esophagus associated with prior daily use of any non-aspirin NSAIDs (fully adjusted OR=1.42, 95% CI=0.92-2.18; I 2 =37%) and ≥5 years of non-aspirin NSAID use (fully adjusted OR=1.57, 95% CI=1.09-2.26; I 2 =7%). However, there were no associations between frequency and duration of non-aspirin NSAID use and the risk of Barrett's esophagus for comparisons with GERD controls ( Table 2 ).
Any NSAIDs
Using data from the six studies, there was no association between regular use of any NSAIDs (adjusted OR=1.00, 0.76-1.32; I 2 =61%) and the risk of Barrett's esophagus for comparison with population-based controls ( ). b Models adjusted for same factors as in footnote a, but also GERD symptoms (less than weekly, at least weekly).
evidence of an inverse relationship between increased frequency or duration of NSAID use and the risk of Barrett's esophagus. We did observe a moderate level of heterogeneity among the studies for many of the eff ect estimates, but with wide UIs, and the associations with NSAID use remained non-signifi cant when individual studies were omitted following "leave-one-out" analyses.
Th ere is consistent evidence from epidemiological studies for an inverse relationship between use of NSAIDs and the risk of esophageal adenocarcinoma. In the largest study to date, pooled analyses of data from BEACON showed greater than 30% reduction in the risk of esophageal adenocarcinoma among NSAID users, as compared with nonusers ( 4 ) . Th e association between NSAID use and esophageal adenocarcinoma was especially strong among daily users (adjusted OR=0.56, 95% CI=0.43-0.73; I 2 =0%). However, there remained considerable uncertainty regarding the stage(s) of neoplastic progression in which NSAIDs may act, whether in preventing the development of Barrett's esophagus, ( Table 2 ) and in analyses (cases vs. population-based controls) stratifi ed by frequency of GERD symptoms ( Table 3 ) .
Although there was evidence of between-study heterogeneity for associations between NSAID use and the risk of Barrett's esophagus, the results remained unchanged in the leave-one-out analysis ( Supplementary Table 3 ), indicating that our results were not driven by any single study.
DISCUSSSION
To our knowledge, this pooled analysis is the largest evaluation of NSAID use and risk of Barrett's esophagus to date. It included six well-characterized population-based case-control studies with similar assessments of regular medication use. We observed no overall association between regular use of any NSAIDs, as well as for the individual eff ects of aspirin and non-aspirin NSAIDs, and the risk of Barrett's esophagus. Furthermore, we found no 
Non-aspirin NSAID use
Nonuser (<weekly use) 1.00 1.00
At least weekly CI, confi dence interval; GERD, gastroesophageal refl ux disease; NSAID, nonsteroidal anti-infl ammatory drug; OR, odds ratio; UI, uncertainty interval. a Models included terms for age (<50, 50-59, 60-69, ≥70 years), sex (except NDB, all male), education (school only, tech/diploma, university), smoking status (never, former, current), and body mass index (<25, 25-29.9, ≥30 kg/m 2 ).
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preventing progression to esophageal adenocarcinoma in patients with Barrett's esophagus, or both. Several well-designed prospective and retrospective studies have examined the association between NSAID use and risk of progression from Barrett's esophagus to esophageal adenocarcinoma. In their recent meta-analysis examining the association with NSAID use, Zhang et al. ( 12 ) showed a 30% reduction in the risk of esophageal adenocarcinoma among patients with Barrett's esophagus (adjusted OR=0.70, 95% CI=0.52-0.95) with minimal heterogeneity between the fi ve studies ( I 2 =28%). Th ey found no signifi cant diff erences in the magnitude in the association with aspirin use or non-aspirin NSAID use and the association was independent of duration of use.
Although several observational studies have assessed the association between NSAID use and the risk of Barrett's esophagus, the results have been inconclusive. Th e reasons for the contrasting results are not clear and diff erences in populations and methods make direct comparisons between published studies diffi cult. We attempted to overcome some of these shortcomings by using harmonized data from multiple well-conducted case-control studies and meta-analytic methods. Regardless, we observed a wide range of results for each of the studies included in this analysis, with results from FINBAR and SRD at the opposite extremes. Th e studies in BEACON were conducted in diff erent countries, over diff erent time periods (from 1997 to 2013), and used diff erent questionnaires for ascertainment of medication use; all of which could have contributed to these diff erences in reported eff ect sizes. Along these lines, it is worth noting that self-reported prevalence of NSAID use among population controls varied from 20% in SDH to over 60% in NDB and the Houston study. However, in a series of sensitivity analyses (based on study period, recent vs. lifetime use) and in the leave-oneout analysis, the null fi ndings were essentially unchanged.
Intriguingly, although we consistently found no association with aspirin use, we observed some evidence for higher risk of Barrett's esophagus associated with both daily use and use >5 years of nonaspirin NSAIDs. It is not clear why there would be a diff erence in associations with non-aspirin NSAIDs and aspirin; it is possible that there may be some kind of interplay between prostaglandins, which causes infl ammation, changes in DNA, and increased carcinogenesis. Alternatively, the non-aspirin NSAID association may in part be due to alternate prescribing trends for the cases (who are more likely to have GERD symptoms and be obese), taking non-aspirin NSAIDs as a substitute for aspirin because they are milder on the stomach.
It is biologically plausible that NSAID use may reduce risk of neoplastic progression in patients with Barrett's esophagus. NSAID use is associated with a reduction in the risk of other gastrointestinal cancers, and also reduces the rate of cancer progression in precancerous lesions. Th ese eff ects are postulated to occur by inhibiting COX-2 enzyme production and retarding tumor growth promoted by prostaglandins ( 22, 23 ) . Studies have shown elevated COX-2 expression in Barrett's esophagus, and also increased COX-2 expression associated with neoplastic progression from Barrett's esophagus to esophageal adenocarcinoma ( 24, 25 ) . Furthermore, experimental studies have found that treating Barrett's esophagus cells with COX-2 inhibitors can inhibit cell growth ( 26, 27 ) . However, data are limited in humans and we await the results of the ASPECT trial which randomized patients with Barrett's esophagus to aspirin and proton-pump inhibitors with a view to inhibiting cancer ( 28 ) .
Th e results from our study have implications for chemoprevention. If NSAIDs stopped the development of Barrett's esophagus, the target group for treatment would be 40% of the population to decrease a fraction of the 10,000 esophageal adenocarcinoma cases in the US every year. Given that NSAIDs are not benign, it is unlikely that such an eff ort is either worthwhile or feasible. If, on the other hand, NSAIDs work aft er the development of Barrett's esophagus, we have a more reasonable strategy whereby we treat a much smaller group of patients at much higher risk to achieve chemoprevention.
Th is large pooled analysis of individual-level participant data from six case-control studies in BEACON off ered several notable strengths. With almost 1,500 cases of Barrett's esophagus, we had greater power to detect associations, if present, than in any of the previous single-site studies. Furthermore, because we were able to evaluate NSAID exposure compared with a common reference group (non-regular use), we reduced the potential for exposure misclassifi cation. Although we observed moderate heterogeneity across studies, we found no evidence that any individual study was overly infl uential, thus providing additional robustness and confidence to our fi ndings. Finally, the use of individual-level data, with variables standardized across studies, and the ability to control for a wide range of potential confounders collected consistently across the studies were additional strengths of this pooled analysis.
Our study also has a number of limitations. Th ere was some variability among the exposure questions from diff erent studies; in particular, the defi nition of regular use. We addressed the misclassifi cation of exposure defi nition across the studies by using a standard defi nition for regular use as described in the "Methods" section; in the one study that did not specify regular use ( 16 ), we reclassifi ed participants accordingly. Because of the way in which the individual studies asked participants about medication use (e.g., "have you used NSAIDs at least weekly in the past year?"), we were unable to examine separately "no use" vs. "low use" of NSAIDs. Th e individual study ORs may diff er somewhat from the pooled ORs due to diff erences in confounding structure. For example, race was a strong confounder of the association between NSAID use and risk of Barrett's esophagus in KPNC ( 14 ) . Here, we limited the analyses to non-Hispanic white study participants. Finally, most of the six studies included a mix of patients with newly diagnosed and prevalent diagnoses of Barrett's esophagus, which could have biased the results unpredictably.
In summary, this pooled analysis found no evidence for an inverse association between use of NSAIDs and the risk of Barrett's esophagus. Given the known inverse association between NSAIDs and the risk of esophageal adenocarcinoma, and analogous to that observed for colon cancer and polyps whereby NSAID use may stop progression from pre-cancer to cancer, these fi ndings support investigations into the use of these chemopreventive agents for decreasing the risk of neoplastic progression from Barrett's esophagus to esophageal adenocarcinoma.
